Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2011

View Archived Issues

TopoTarget patents new NAmPRTase inhibitors

Cellzome discloses novel tyrosine-protein kinase ZAP-70 inhibitors

Abraxis claims new proto-oncogene tyrosine-protein kinase Src inhibitors

New inhibitors claimed of DNA gyrase and/or DNA topoisomerase 4

Anticocaine vaccine dAd5GNC shows promise in mice

Methylation of FMR1 promoter may predict response to AF-Q056 in fragile X syndrome

GSK discloses new lysophospholipid S1P1 receptor agonists

Merck & Co. patents new Egl nine homolog inhibitors

Amgen grants MedImmune rights to develop AMG-108 worldwide outside Japan

Profectus' multiantigen HIV pDNA vaccine enters phase I trial

ATX-101 enters European phase III trials for reduction of submental fat

Bristol-Myers Squibb and AstraZeneca launch Kombiglyze in U.S.

Eusa Pharma obtains FDA priority review status for Erwinaze BLA

FDA approves Abstral for breakthrough cancer pain

EMA and FDA grant expedited review for boceprevir

Rivaroxaban filed for approval in E.U. and U.S. for stroke prevention and other indications

Enrollment begins in phase III regorafenib trial in gastrointestinal stromal tumors

New indication for Lucentis in E.U. for vision loss in diabetic macular edema

EB-1010 improves symptoms of major depressive disorder

Forest Laboratories launches Teflaro in U.S.

Inhibitex reports interim safety and antiviral data from phase Ib INX-189 trial

ELN-457946 reduces restenosis in porcine model combining endothelial denudation and stent placement

Acceleron receives grant to develop ACE-031 for DMD

Sandoz initiates phase II trial of its biosimilar rituximab

Lexicon reports phase II data on LX-4211 in type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...